Showing results (1341-1350 of 5,501) with videos related to
Sort By:
Pageof 551
Inflammatory Bowel Diseases|March 11, 2021
Targeting Immune Cell Metabolism in the Treatment of Inflammatory Bowel DiseaseVanessa Zaiatz Bittencourt, Fiona Jones, Glen Doherty, et al.Inflammatory Bowel Diseases|July 23, 2026
Classifications of rheumatological extraintestinal manifestations in inflammatory bowel disease: Unmet needs in clinical practice and trialsOlga Maria Nardone, Yuhong Yuan, Francesco Caso, et al.Inflammatory Bowel Diseases|July 21, 2026
Appendicectomy in ulcerative colitis: a narrative review of epidemiology, pathophysiology, and emerging therapeutic implicationsM Juwanwarnage Nuwanthi Rashika Vanojan, Oluwalanoayo Oluwadara Agbabiaka, Devya Kumaresan, et al.Inflammatory Bowel Diseases|July 22, 2026
Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort studyNalan Gülşen Ünal, Oğuz Kağan Bakkaloğlu, Taylan Kav, et al.Inflammatory Bowel Diseases|August 7, 2026
Multi-modal ensemble learning prediction of anti-TNF treatment response in pediatric patients with Crohn's disease using clinical, radiomic, and deep learning MR enterography featuresHailong Li, Zhixiu Lu, Nicholas Denson, et al.Inflammatory Bowel Diseases|August 12, 2026
Prior adalimumab exposure alters infliximab pharmacokinetics and trough targets in pediatric Crohn's diseaseYiyoung Kwon, Yoon Zi Kim, Tae Jong Jeong, et al.Inflammatory Bowel Diseases|August 19, 2026
Coccidioidomycosis in patients with inflammatory bowel disease receiving advanced therapy: An observational study from an endemic tertiary centerFares Jamal, Alejandro J Gonzalez, Geoff Thomas, et al.Inflammatory Bowel Diseases|August 18, 2026
Hormonal contraception is not associated with recurrent flares in ulcerative colitis: a longitudinal time-dependent analysisBeatriz Gros, Carlos Frutos, Eduard Brunet, et al.Inflammatory Bowel Diseases|August 18, 2026
Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study)Shih-Hua Lin, Chia-Jung Kuo, Chiao-Hsiung Chuang, et al.Inflammatory Bowel Diseases|August 7, 2026
Sarcopenia as a prognostic marker in inflammatory bowel disease: Implications for endoscopic outcomes and loss of response to biologic therapy-A systematic review with narrative synthesisThomas Fuchs, Vanessa StadlbauerPageof 551